{
    "clinical_study": {
        "@rank": "19872", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability and the pharmacokinetics\n      of BAY1082439"
        }, 
        "brief_title": "Open Label Study of BAY1082439 in Patients With Advanced Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with advanced, histologically or cytologically confirmed solid tumors,\n             refractory to any standard therapy, have no standard therapy available, or subjects\n             must have actively refused any treatment which would be regarded standard, and / or\n             if in the judgment of the investigator, experimental treatment is clinically and\n             ethically acceptable\n\n          -  International normalized ratio (INR) and partial thromboplastin time (PTT) <1.5 x ULN\n             [Subjects on anticoagulation with an agent such as coumadin or heparin will be\n             allowed to participate provided that no prior evidence of underlying abnormality in\n             these parameters exists.] For subjects on warfarin, close monitoring of at least\n             weekly evaluations will be performed until INR is stable based on a measurement at\n             pre-dose, as defined by the local standard of care\n\n          -  Measurable or evaluable disease\n\n          -  Life expectancy of at least 12 weeks\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\n          -  Adequate bone marrow, liver and renal function\n\n        Exclusion Criteria:\n\n          -  History of cardiac disease: congestive heart failure > New York Heart Association\n             (NYHA) Class II, unstable angina (anginal symptoms at rest), new-onset angina (within\n             the past 3 months prior to the first dose of study drug), myocardial infarction\n             within the past 6 months prior to the first dose of study drug, or cardiac\n             arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are\n             permitted)\n\n          -  Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic\n             pressure > 90 mmHg, despite optimal medical management\n\n          -  History of diabetes mellitus or gestational diabetes mellitus\n\n          -  Fasting blood glucose level >125 mg/dL or HbA1c 7% at screening\n\n          -  Active clinically serious infections > Grade 2\n\n          -  History of organ allograft\n\n          -  Seizure disorder requiring therapy (such as steroids or anti-epileptics)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728311", 
            "org_study_id": "15734"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "description": "BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.", 
            "intervention_name": "BAY1082439", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "120-752"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul Teugbyeolsi", 
                        "zip": "110-744"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "119228"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10016"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Korea, Republic of", 
                "Singapore", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1082439 Given Once Daily in Subjects With Advanced Malignancies", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_contact_backup": {
            "last_name": "For trial location information (Phone Menu Options '3' or '4')", 
            "phone": "(+)1-888-84 22937"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Singapore: Health Sciences Authority", 
                "Korea: Food and Drug Administration", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Maximum tolerated dose of BAY1082439", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Area under the plasma concentration of BAY1082439 versus time curve (AUC) after a single dose", 
                "safety_issue": "No", 
                "time_frame": "Day 1  to Day 3:  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24,36 and 48 hours post-dose; Day 8: pre-dose, 0.5, 1, 2 hours post-dose; Day 15 to Day 16:  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728311"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Maximum total bound drug concentration (Cmax) in plasma after single dose administration", 
            "safety_issue": "No", 
            "time_frame": "Day 1  to Day 3:  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose; Day 8:  pre-dose, 0.5, 1, and 2 hours post-dose; Day 15 to Day 16:  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}